Rheumnow Podcast

This week on the RheumNow Podcast, Dr. Jack Cush reviews the news and journal reports of interesting, including irAE, pollution and Psoriasis, microwave therapy, scleroderma without scleroderma that only the best rheumatologists could discern.

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com  

Dr. Jack Cush discusses outdated terms in rheumatology, promoting more accurate terminology like 'CREST' and 'Churg Strauss'. He explores the evolution of fibromyalgia terminology, advocates for precise anatomical language, and delves into the historical context of Lumbago. Dr. Cush highlights the shift to scientifically accurate terms in rheumatology and the importance of precise terminology in medical communication.

Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com

Panel discussion led by rheumatology experts Drs. Aurelie Najm, David Liew, and Jonathan Kay at EULAR 2024 meeting. Topics include disappointing trial results for bio-naive patients, challenges in treatment selection, importance of addressing depression, impact of medications on vaccination responses, debate on therapeutic drug monitoring in RA treatment, and use of innovative apps for remote patient monitoring in rheumatoid arthritis.

Rheumatology specialists Drs. Cush, Yusof, and Fava discuss cutting-edge lupus therapies at EULAR 2024 conference. Topics include steroid reduction strategies, B-cell targeting meds, and promising results of ionolumab for cell depletion. They delve into Lupus treatment trials, advances in lupus nephritis therapies, biomarkers for disease activity prediction, and the dynamic nature of lupus nephritis.

Moderated by Dr. Jack Cush and Featuring Drs. Eric Ruderman, Antoni Chan, and Peter Nash

Drs. Kavanaugh and Cush discuss topics from the EULAR 2024 Meeting, including the impact of anxiety on disease activity in RA patients, challenges in treating difficult cases of RA and psoriatic arthritis, recognizing and addressing depression symptoms, and exploring studies on ILD in RA patients. They also cover the use of AI in treatment analysis, CAR-T therapy for autoimmune diseases, and the efficacy of Dukravicitinib in managing lupus skin conditions.

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria: OP0195 Sonelokimab IL 17 A/F nanobody inhibitor LB0005 Izokibep IL17A nanobody inhibitor POS0803 Vunakizumab, another IL17A inhibitor OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib Giant Cell Arteritis and Polymyalgia Rheumatica Update Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria. JAK Inhibitors for New Indications Dr. Janet Pope discusses new indications for JAK inhibitors, reporting from Eular 2024 in Vienna, Austria. Pain in RA: Different Drugs for Different Mechanisms Dr. Aurelie Najm reports from Eular 2024 in Vienna, Austria, about abstracts OP0072 and OP0086. Top 3 Messages About JAK Inhibitor Safety Dr. Janet Pope discusses a debate she participated in at Eular 2024 in Vienna, Austria, and her top three messages regarding JAKi safety. DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. Select your GCA Therapy Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.  

Dr. Eric Ruderman discusses IL-17 and JAK Inhibitors in Spondyloarthritis and research abstracts presented at Eular 2024. Topics include MRI changes, telemonitoring effectiveness, radiomics predicting therapy outcomes, treating to target outcomes, early diagnosis of Axial Spondyloarthritis, and imaging in Axial Spondyloarthritis.